Tag Archives: generic drugs

Lupin Expecting Approval to Enter US Generic Market

Mumbai-based Lupin Pharmaceuticals is expecting approval from US health regulators to launch about 30 generic drugs into the US market, the world’s largest for pharmaceuticals. At the moment the company has 162 abbreviated new drug applications (ANDAs) which are waiting for approval from the USFDA, (United States Food and Drug Administration.)

The company has its sights set on bringing complex generic drugs and biosimilars to the US market, in addition to continuing to focus on several exclusive and semi-exclusive products in the injectable and oral niche to keep its place as the fourth largest generics company in the market by prescriptions sold.

“We launched 23 products in the US last fiscal (2017-18), with 10 in the last quarter (January-March) alone. We expect to launch 25-30 products in US this year,” Lupin Managing Director Nilesh Gupta.

“Our efforts to maintain leadership position include bringing complex generics and biosimilars to market while continuing our focus on exclusive and semi-exclusive products in the oral and injectable space,” Gupta said.

During the fiscal year 2018 the company is hoping to launch about 30 specific products in to the US market.

Generic Drug Makers Bought by Pharmaceutical Giants

In a move that will make Hikma Pharmaceuticals Plc the sixth largest US generic drug provider, the Jordanian company said it is going to purchase the German drug manufacturer Boehringer Ingelheim’s US specialty generic drugs business. The deal is worth an estimated $2.65 billion in cash and stock.

The company’s stock climbed 8 percent on late Tuesday trading. Previously the stock had fallen about 13 percent since it was included in the British benchmark FTSE 100.

The sale is just one more in a series of high profile deals in the generics sector. On Monday Israeli company Teva Pharmaceutical Industries announced it will purchase Allergan’s generic drug business for $40.5 billion. This move serves to strengthen Teva’s position as the world’s largest producer of generics.